Kurs & Likviditet
|Lista||First North Stockholm|
|2022-05-12||Ordinarie utdelning SEDANA 0.00 SEK|
|2021-05-26||Split SEDANA 1:4|
|2021-05-11||Ordinarie utdelning SEDANA 0.00 SEK|
|2020-05-20||Ordinarie utdelning SEDANA 0.00 SEK|
|2019-05-29||Ordinarie utdelning SEDANA 0.00 SEK|
|2018-05-23||Ordinarie utdelning SEDANA 0.00 SEK|
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces the appointment of Johan Spetz as the company's new Chief Financial Officer (CFO). Johan Spetz will take office no later than April 4, 2022, succeeding Susanne Andersson who will leave her position for another assignment.
Johan Spetz joins Sedana Medical from investment bank Pareto Securities AB where he has been a partner for 8 years and headed up the Equity Research team in Stockholm for 6 years. Previously, Johan worked at Goldman Sachs in New York.
"We are delighted to welcome Johan to Sedana Medical. His strong financial background, deep understanding of companies' value drivers, long track record of working with international investors, as well as his drive and motivation will be important assets for Sedana Medical going forward," said Johannes Doll, CEO of Sedana Medical.
"I have followed Sedana Medical's impressive journey closely over several years and I feel honoured and happy to join the company at this exciting time as the European launch is gearing up and preparations for the US market are intensifying. I look forward to becoming part of a great team and to contribute to Sedana Medical's successful development, establishing inhaled sedation as a new global standard therapy for patients in intensive care," said Johan Spetz.
Johannes Doll added: "The Board of Directors and I would like to thank Susanne for her extensive commitment and efforts during her time at Sedana Medical. We wish her the best of luck with her new challenges."
Susanne Andersson will continue in her current role until a successful hand-over of work tasks has been completed.
For additional information, please contact:
Johannes Doll, CEO, +46 76 303 66 66
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, email@example.com.
The information was released for public disclosure, through the agency of the contact person above, on January 20, 2022 at 08:30 am. (CET).
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.